Technical Analysis for DBTX - Decibel Therapeutics, Inc.

Grade Last Price % Change Price Change
F 7.09 -0.56% -0.04
DBTX closed down 0.56 percent on Friday, July 23, 2021, on 26 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A Down Flat
Historical DBTX trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -0.56%
Narrow Range Bar Range Contraction -0.56%
NR7 Range Contraction -0.56%
NR7-2 Range Contraction -0.56%
Inside Day Range Contraction -0.56%
Wide Bands Range Expansion -0.56%
Oversold Stochastic Weakness -0.56%
Older End-of-Day Signals for DBTX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Decibel Therapeutics, Inc. Description

Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. Its product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations; Gene Therapies for Hair Cell Regeneration designed to replace lost hair cells within the inner ear to address acquired hearing loss and balance disorders; and Otoprotection Therapeutic in clinical development to prevent hearing loss in cancer patients undergoing chemotherapy with cisplatin. The company's lead gene therapy product candidate is DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin, or OTOF, gene. It is also developing DB-ATO, a gene therapy program designed to restore balance in patients with bilateral vestibulopathy, or BVP, by regenerating lost hair cells within the inner ear; and DB-020 for the prevention of cisplatin-induced hearing loss, which is in Phase 1b clinical trial. Decibel Therapeutics, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop gene therapies for monogenic forms of congenital hearing loss. The company was formerly known as Hearing Inc. and changed its name to Decibel Therapeutics, Inc. in April 2014. Decibel Therapeutics, Inc. was founded in 2013 and is based in Boston, Massachusetts.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Biology Chemotherapy Gene Therapy Occupational Safety And Health Hearing Audiology Hearing Loss Deafness Auditory System Balance Disorders Hair Cell

Is DBTX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 24.39
52 Week Low 6.18
Average Volume 133,422
200-Day Moving Average 0.00
50-Day Moving Average 7.98
20-Day Moving Average 7.72
10-Day Moving Average 7.12
Average True Range 0.63
ADX 14.48
+DI 14.87
-DI 19.47
Chandelier Exit (Long, 3 ATRs) 7.87
Chandelier Exit (Short, 3 ATRs) 8.48
Upper Bollinger Bands 9.22
Lower Bollinger Band 6.22
Percent B (%b) 0.29
BandWidth 38.87
MACD Line -0.37
MACD Signal Line -0.33
MACD Histogram -0.0393
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 7.55
Resistance 3 (R3) 7.55 7.40 7.47
Resistance 2 (R2) 7.40 7.28 7.40 7.45
Resistance 1 (R1) 7.25 7.21 7.17 7.24 7.42
Pivot Point 7.10 7.10 7.06 7.09 7.10
Support 1 (S1) 6.94 6.98 6.87 6.94 6.76
Support 2 (S2) 6.79 6.91 6.79 6.73
Support 3 (S3) 6.64 6.79 6.71
Support 4 (S4) 6.63